JP2024534156A - Ｎｕｒｒ１アゴニストの、アルドステロンアンタゴニスト、インスリンモジュレーター及びスルホニル尿素のうちの少なくとも１つとの組合せ - Google Patents

Ｎｕｒｒ１アゴニストの、アルドステロンアンタゴニスト、インスリンモジュレーター及びスルホニル尿素のうちの少なくとも１つとの組合せ Download PDF

Info

Publication number
JP2024534156A
JP2024534156A JP2024513002A JP2024513002A JP2024534156A JP 2024534156 A JP2024534156 A JP 2024534156A JP 2024513002 A JP2024513002 A JP 2024513002A JP 2024513002 A JP2024513002 A JP 2024513002A JP 2024534156 A JP2024534156 A JP 2024534156A
Authority
JP
Japan
Prior art keywords
pharma
acceptable salt
ceutically acceptable
amodiaquine
structural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534156A5 (https=
Inventor
ジョージ ヴォギアツィス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genesis Pharma SA
Original Assignee
Genesis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesis Pharma SA filed Critical Genesis Pharma SA
Publication of JP2024534156A publication Critical patent/JP2024534156A/ja
Publication of JP2024534156A5 publication Critical patent/JP2024534156A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024513002A 2021-08-27 2022-08-26 Ｎｕｒｒ１アゴニストの、アルドステロンアンタゴニスト、インスリンモジュレーター及びスルホニル尿素のうちの少なくとも１つとの組合せ Pending JP2024534156A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR20210100572 2021-08-27
GR20210100572 2021-08-27
PCT/IB2022/058008 WO2023026247A1 (en) 2021-08-27 2022-08-26 Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea

Publications (2)

Publication Number Publication Date
JP2024534156A true JP2024534156A (ja) 2024-09-18
JP2024534156A5 JP2024534156A5 (https=) 2025-09-02

Family

ID=83598699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513002A Pending JP2024534156A (ja) 2021-08-27 2022-08-26 Ｎｕｒｒ１アゴニストの、アルドステロンアンタゴニスト、インスリンモジュレーター及びスルホニル尿素のうちの少なくとも１つとの組合せ

Country Status (5)

Country Link
US (1) US20240366729A1 (https=)
EP (1) EP4392033A1 (https=)
JP (1) JP2024534156A (https=)
CN (1) CN118284417A (https=)
WO (1) WO2023026247A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265776A1 (en) * 2019-07-09 2022-08-25 Genesis Pharma Sa Combination

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140256626A1 (en) 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide
ES2791301T3 (es) * 2015-11-06 2020-11-03 Genesis Pharma Sa Combinación de canrenoato y exenatida
EP3498279A4 (en) * 2016-08-12 2020-04-29 Novmetapharma Co., Ltd. PHARMACEUTICAL COMPOSITION WITH AMODIAQUIN AND ANTIDIABETIC MEDICINAL PRODUCT AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING DIABETES
US20220265776A1 (en) 2019-07-09 2022-08-25 Genesis Pharma Sa Combination

Also Published As

Publication number Publication date
WO2023026247A1 (en) 2023-03-02
US20240366729A1 (en) 2024-11-07
CN118284417A (zh) 2024-07-02
EP4392033A1 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
CN1856339A (zh) 肺动脉高血压症治疗的伊洛前列素联合疗法
KR101951220B1 (ko) 조합 als 치료법
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
JP2024056908A (ja) デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
JP7758655B2 (ja) 組合せ
US20240366729A1 (en) Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea
JP7854206B2 (ja) 肺線維症の予防または治療用の薬学製剤
US10172914B2 (en) Combination
JP7745571B2 (ja) 肺線維症を処置する方法
JP2017508768A (ja) サルビノリン組成物およびその使用
US11000505B2 (en) Salvinorin compositions and uses thereof
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
JP7569492B2 (ja) 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
TW201806599A (zh) 用於快速開始抗抑鬱作用之給藥方案
AU2011202639A1 (en) Compositions and methods for treating myelodysplastic syndrome
AU2002366975B2 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
US20230028539A1 (en) Pharmaceutical composition, complementary kit and application thereof
RU2696100C1 (ru) Применение ксенона, иммобилизированного в носителе в средстве для повышения резистентности организма к гипоксии
KR20150105496A (ko) 다폭세틴 및 염산클로미프라민으로부터 선택되는 조루치료제 및 pde5 억제제가 분리된 형태로 존재하는 경구투여 약제학적 제형
MX2015003810A (es) Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250825